Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 244 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Osteoarthritis (OA) Clear all

Conditions: Knee Osteoarthritis
Interventions: Sustained Acoustic Device with 2.5% Diclofenac Patch, 1% Diclofenac Topical Gel; Device · Drug
Lead sponsor: ZetrOZ, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York

Conditions: Musculoskeletal Diseases
Interventions: Multimedia Patient Decision Aids (MM-PtDAs), Comparative Effectiveness Research Summary Guide (CERSG), Questionnaires; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 676 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee
Interventions: Acupuncture; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Osteoarthritis
Interventions: tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo; Biological · Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more

Conditions: Knee Osteoarthritis (OA), Chronic Pain, Chronic Knee Pain
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteo Arthritis Knee
Interventions: Cognitive-Behavioral Intervention, Pain Education; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Osteoarthritis
Interventions: I'm Walking, Walk With Ease; Behavioral · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis
Interventions: naproxen, CE-224535, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 46
States / cities: Anniston, Alabama • Bayou La Batre, Alabama • Birmingham, Alabama + 39 more

Conditions: Osteoarthritis, Knee
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: El Cajon, California • La Mesa, California • Pomona, California + 5 more

Conditions: Osteoarthritis
Interventions: Supartz, Euflexxa; Device
Lead sponsor: Bioventus LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoarthritis
Interventions: Patient education in self-care of knee OA; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Knee Osteoarthritis, Cartilage Degeneration
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Christopher Ritchlin; Other
Eligibility: 40 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more

Conditions: Osteo Arthritis Knee
Interventions: V120083, Naproxen, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 30
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: Osteoarthritis, Knee
Interventions: Aquatic Prehab; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Pain, Osteoarthritis
Interventions: active low-intensity transcranial electrical stimulation/active transcranial ultrasound, Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Chronic Pain, Osteoarthritis
Interventions: transcranial direct current stimulation (tDCS), transcranial ultrasound (TUS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Pain
Interventions: Tramadol HCl ER; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions: TTAX03, Saline; Biological
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more

Conditions: Osteoarthritis of the Knee
Interventions: Hydroxychloroquine/Atorvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Knee Osteoarthritis
Interventions: Virtual Reality; Device
Lead sponsor: Tufts University; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Osteoarthritis
Interventions: Coping skills training (CST) for chronic pain, Usual care; Behavioral · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Setauket, New York • Smithtown and Port Jefferson, New York • Danville, Virginia

Search by objective public record fields.

Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain

IADAPT-Third Phase

fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Tanezumab in Osteoarthritis of the Hip or Knee (2)

Individual Differences in Gait and Osteoarthritis Pain

Study of Pain Catastrophizing

Study Comparing Osteoarthritis Programs

A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA

Effects of Comprehensive Care for Knee OA

Teriparatide as a Chondroregenerative Therapy in OA

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Prehabilitation Using Aquatic Exercise

Effects of tDCS and tUS on Pain Perception in OA of the Knee

Effects of tDCS and tUS on Pain Perception in OA of the Knee

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

Virtual Reality and Older Adult Knee OA

Effectiveness of a Training Program in Improving Coping Skills in People With Arthritis Pain